The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone

Previous studies have shown that bispecific antibodies that target both CD20 and CD22 have in vivo lymphomacidal properties. We developed a CD20-CD22 bispecific antibody (Bs20x22) from anti-CD20 and the anti-CD22 monoclonal antibodies (mAb), rituximab and HB22.7, respectively. Bs20x22 was constructe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuscano, Joseph M., Ma, Yunpeng, Martin, Shiloh M., Kato, Jason, O’Donnell, Robert T.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098984/
https://www.ncbi.nlm.nih.gov/pubmed/21347809
http://dx.doi.org/10.1007/s00262-011-0978-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098984/
https://www.ncbi.nlm.nih.gov/pubmed/21347809
http://dx.doi.org/10.1007/s00262-011-0978-6

Ejemplares similares